



## Clinical trial results:

**Effect of high versus low dose intravenous dexamethason on complications in the immediate postoperative setting after periacetabular osteotomy- a randomized, double-blind, controlled trial.**

### Summary

EudraCT number	2017-000544-17
Trial protocol	DK
Global end of trial date	20 September 2019

### Results information

Result version number	v1 (current)
This version publication date	19 April 2020
First version publication date	19 April 2020

### Trial information

#### Trial identification

Sponsor protocol code	DEXGANZ01
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03161938
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Eske K Aasvang
Sponsor organisation address	Blegdamsvej 9, Copenhagen, Denmark, 2100
Public contact	Kristin Julia Steinhorsdottir, Rigshospitalet, 0045 31666112, kjs@dadlnet.dk
Scientific contact	Kristin Julia Steinhorsdottir, Rigshospitalet, 31666112 31666112, kjs@dadlnet.dk

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 February 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 September 2019
Global end of trial reached?	Yes
Global end of trial date	20 September 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To investigate the effects of high versus low dose glucocorticoids on pain after periacetabular osteotomy

Protection of trial subjects:

All trial subjects underwent standard procedures, only difference was the dosage of dexamethasone

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 March 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 64
Worldwide total number of subjects	64
EEA total number of subjects	64

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	64
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Denmark, 1/5-2017 to 20/8-2019

### Pre-assignment

Screening details:

Eligible patients are informed about the trial in relation to the pre-operative appointment. Enrolled participants are randomized and assigned to consecutive numbers (1-64) at the morning of surgery.

Inclusion criteria

- Planned PAO
- Age 18 years or older
- Able to understand Danish or English and to provide informed oral and written consent

### Period 1

Period 1 title	overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	48 mg dexamethasone

Arm description:

48 mg dexamethasone

Arm type	Experimental
Investigational medicinal product name	dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection
Routes of administration	Intravenous bolus use

Dosage and administration details:

single-dose intravenous

<b>Arm title</b>	8 mg dexamethasone
------------------	--------------------

Arm description:

8 mg dexamethasone

Arm type	Active comparator
Investigational medicinal product name	dexamethasone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection
Routes of administration	Intravenous bolus use

Dosage and administration details:

single-dose intravenous

<b>Number of subjects in period 1</b>	48 mg dexamethasone	8 mg dexamethasone
Started	32	32
Completed	32	32

## Baseline characteristics

### Reporting groups

Reporting group title	overall
-----------------------	---------

Reporting group description: -

Reporting group values	overall	Total	
Number of subjects	64	64	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	29		
standard deviation	± 8	-	
Gender categorical			
Units: Subjects			
Female	51	51	
Male	13	13	

## End points

### End points reporting groups

Reporting group title	48 mg dexamethasone
Reporting group description:	
48 mg dexamethasone	
Reporting group title	8 mg dexamethasone
Reporting group description:	
8 mg dexamethasone	

### Primary: Pain in the PACU

End point title	Pain in the PACU
End point description:	
The primary endpoint was the proportion of patients reporting moderate to severe pain at rest (>3 out of 10 on a Numeric Rating Scale from 0-10 (NRS)) in the immediate postoperative phase (after extubation in the operating room, and in the PACU until transfer to the ward).	
End point type	Primary
End point timeframe:	
12 hours	

End point values	48 mg dexamethasone	8 mg dexamethasone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	32		
Units: participants	26	22		

### Statistical analyses

Statistical analysis title	primary outcome fishers
Comparison groups	48 mg dexamethasone v 8 mg dexamethasone
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.248
Method	Chi-squared corrected
Parameter estimate	Odds ratio (OR)
Point estimate	0.508
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.159
upper limit	1.62



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

60 hours after administration of trial drug

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	SNOMED CT
-----------------	-----------

Dictionary version	10
--------------------	----

### Reporting groups

Reporting group title	48 mg dexamethasone
-----------------------	---------------------

Reporting group description:

48 mg dexamethasone

Reporting group title	8 mg dexamethasone
-----------------------	--------------------

Reporting group description:

8 mg dexamethasone

Serious adverse events	48 mg dexamethasone	8 mg dexamethasone	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 32 (3.13%)	0 / 32 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Surgical and medical procedures			
Arterial injury	Additional description: gluteal artery damage, iatrogenic intraoperative		
subjects affected / exposed	1 / 32 (3.13%)	0 / 32 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	48 mg dexamethasone	8 mg dexamethasone	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 32 (21.88%)	4 / 32 (12.50%)	
Ear and labyrinth disorders			
Dizziness postural	Additional description: dizziness at mobilization		
subjects affected / exposed	7 / 32 (21.88%)	4 / 32 (12.50%)	
occurrences (all)	7	4	





## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported